EGFR and non-small cell lung carcinoma: Our study demonstrates that standard chemotherapy still should be considered in the perioperative setting for high-risk patients, when taking pathological risk factors into consideration, and that optimized sequencing of EGFR–TKIs might be the most critical determinant of OS in patients with stage III EGFR-mutant NSCLC.